治疗顺序为何重要:化疗周期数与累积剂量强度对可切除早期胰腺癌术后生存的交互影响
该单中心回顾性研究纳入2010–2021年225例I/II期胰腺导管腺癌(PDAC)切除患者,分析围手术期化疗完成周期数与相对剂量强度(RDI)和总生存(OS)的关系。结果显示完成≥67%推荐周期或≥56%累积RDI与OS改善相关,新辅助化疗与更高完成度相关。
要点
- 完成≥67%推荐化疗周期与OS改善相关,中位OS 34.5 vs 18.1个月。
- 累积RDI≥56%与OS改善相关,中位OS 35.5 vs 18.1个月。
- 新辅助化疗与完成≥67%周期及≥56% RDI的几率增加相关。
核心结论
- 接受≥67%推荐化疗周期或≥56%累积RDI的PDAC切除患者OS改善。
- 新辅助治疗与接受≥67%周期和≥56%累积RDI的几率增加相关,应考虑用于所有可切除PDAC患者。
研究设计与样本
- 单中心回顾性分析2010–2021年225例接受胰腺切除术的I/II期PDAC患者。
- 分析化疗完成周期数、RDI与OS之间的关联。
主要发现
- 完成≥67%推荐周期相比无化疗:中位OS 34.5 vs 18.1个月,HR 0.43(95%CI 0.25-0.74)。
- 完成≥67%推荐周期相比<67%周期:中位OS 34.5 vs 17.9个月,HR 0.39(95%CI 0.24-0.64)。
- 完成周期数与RDI呈近线性关系(β=0.82),RDI中位数56%对应完成67%周期。
- RDI≥56%相比无化疗:中位OS 35.5 vs 18.1个月,HR 0.44(95%CI 0.23-0.84)。
- RDI≥56%相比<56%:中位OS 35.5 vs 27.2个月,HR 0.44(95%CI 0.20-0.96)。
关键数值与推荐
- 完成≥67%推荐化疗周期为与OS改善相关的阈值。
- 累积RDI≥56%为与OS改善相关的阈值。
- 新辅助化疗与接受≥67%周期相关:OR 2.94(95%CI 1.45-6.26)。
- 新辅助化疗与接受≥56% RDI相关:OR 4.47(95%CI 1.72-12.50)。
临床怎么用
- 可切除PDAC患者应优先考虑新辅助化疗以提高化疗完成度。
- 围手术期化疗管理应关注完成≥67%周期或累积RDI≥56%的目标。
局限性
- 单中心回顾性分析,样本量225例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the optimal threshold of perioperative chemotherapy completion and relative dose intensity (RDI) for patients with resected pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Many patients who undergo pancreatectomy for PDAC fail to initiate or complete recommended perioperative chemotherapy. The association between the amount of perioperative chemotherapy received and overall survival (OS) is not well-defined. METHODS: Single-institution analysis of 225 patients who underwent pancreatectomy for stage I/II PDAC (2010-2021). Associations between OS, chemotherapy cycles completed, and RDI were analyzed. RESULTS: Regardless of treatment sequence, completion of ≥67% of recommended cycles was associated with improved OS compared with no chemotherapy [median OS: 34.5 vs 18.1 months; hazard ratio (HR): 0.43; 95% CI: 0.25-0.74] and <67% of cycles (median OS: 17.9 months; HR: 0.39; 95% CI: 0.24-0.64). A near-linear relationship existed between cycles completed and the RDI received (β = 0.82). A median RDI of 56% corresponded to the completion of 67% of cycles. Receipt of ≥56% RDI was associated with improved OS compared with no chemotherapy (median OS: 35.5 vs 18.1 months; HR: 0.44; 95% CI: 0.23-0.84) and <56% RDI (median OS: 27.2 months; HR: 0.44; 95% CI: 0.20-0.96). Neoadjuvant chemotherapy is associated with increased odds of receiving ≥67% of recommended cycles (odds ratio: 2.94; 95% CI: 1.45-6.26) and ≥56% RDI (odds ratio: 4.47; 95% CI: 1.72-12.50). CONCLUSIONS: Patients with PDAC who received ≥67% of recommended chemotherapy cycles or ≥56% cumulative RDI had improved OS. Neoadjuvant therapy was associated with increased odds of receiving ≥67% of cycles and ≥56% cumulative RDI and should be considered in all patients with resectable PDAC.
引用
- Wu VS, Elshami M, Stitzel HJ, et al. Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer. Ann Surg. 2023. PMID: 37071769. doi:10.1097/SLA.0000000000005830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。